Therefore, blocking either HDAC and/or tyrosine kinase cell-cycle progression regulator WEE1 may represent therapeutic vulnerabilities in these tumors, potentially restoring their tumor immunogenicity. This evidence concerns the gene HDAC9 and neoplasm.